Published in Hepatitis Weekly, March 6th, 2000
The selection of hepatitis C virus (HCV)-related cirrhotic patients for interferon treatment is necessary to improve the efficacy of this treatment.
"Currently, it is impossible to predict which cirrhotic patients will ultimately respond to this treatment with viral clearance," researcher A. Kasahara and colleagues from Osaka University wrote ("Pretreatment viral load and response to interferon therapy for liver cirrhosis caused by hepatitis C virus: A multicenter controlled study,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.